Loading...

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age

INTRODUCTION: Interleukin-1 (IL-1) blockade is the treatment of choice of cryopyrin associated periodic syndromes (CAPS). Anti-IL-1 monoclonal antibody (canakinumab) was recently registered. However no clear data are available on the optimal schedule of administration of this drug. The aim of the pr...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Caorsi, Roberta, Lepore, Loredana, Zulian, Francesco, Alessio, Maria, Stabile, Achille, Insalaco, Antonella, Finetti, Martina, Battagliese, Antonella, Martini, Giorgia, Bibalo, Chiara, Martini, Alberto, Gattorno, Marco
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2013
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3672768/
https://ncbi.nlm.nih.gov/pubmed/23442610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar4184
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!